8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Autor: Bart van Hoek, Bart J. A. Rijnders, Joop E. Arends, Anthonius S. M. Dofferhoff, Marjo E. E. van Kasteren, Guido E.L. van den Berk, Marc van der Valk, Dirk Posthouwer, Thomas Vanwolleghem, Dewkoemar Ramsoekh, Janke Schinkel, Anne Boerekamps, Jelle Koopsen, Eric Florence
Přispěvatelé: Infectious diseases, AII - Infectious diseases, APH - Personalized Medicine, APH - Global Health, Graduate School, Medical Microbiology and Infection Prevention, Other Research, Gastroenterology and hepatology, AGEM - Digestive immunity, Medical Microbiology & Infectious Diseases, Gastroenterology & Hepatology, Internal Medicine, Med Microbiol, Infect Dis & Infect Prev, MUMC+: DA MMI Staf (9), RS: FHML non-thematic output
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Journal of hepatology, 70(3), 554-557. Elsevier
Journal of Hepatology, 70(3), 554-557
Boerekamps, A, Vanwolleghem, T, van der Valk, M, van den Berk, G E, van Kasteren, M, Posthouwer, D, Dofferhoff, A S M, van Hoek, B, Ramsoekh, D, Koopsen, J, Schinkel, J, Florence, E, Arends, J E & Rijnders, B J 2019, ' 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study) ', Journal of Hepatology, vol. 70, no. 3, pp. 554-557 . https://doi.org/10.1016/j.jhep.2018.10.032
Journal of Hepatology, 70(3), 554-557. Elsevier
Journal of hepatology
Journal of Hepatology, 70(3), 554-557. Elsevier Science
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2018.10.032
Databáze: OpenAIRE